

Ancillary events	
Friday 21 June	
09:00-19:00	Muscle-bone interaction in Duchenne Muscular Dystrophy Details here
Saturday 22 June	
07:30-11:50	Foramen magnum stenosis in children with achondroplasia working group Details here

Saturday 22 June

10:00-12:00	<p>Networking – New Investigators Organiser: Alex Ireland (Manchester, UK)</p> <p>How did I get here? Speakers:</p> <p>Rachel Duckham (Melbourne, Australia) Heike Hoyer-Kuhn (Cologne, Germany)</p> <p>Round table discussions with senior investigators:</p> <p>Building your profile and network Disseminating your work Funding your science (and yourself!) Developing your skills</p> <p>Group discussion</p>	<p>Networking - Allied Health Professionals Organiser: Nicola Crabtree (Birmingham, UK)</p> <p>Management of children with severe osteogenesis imperfecta Jas Sahota (Birmingham, UK)</p> <p>Patient experiences seen through “Stop Motion” animation Kirandeep Basraka (Birmingham, UK)</p> <p>New treatment in XLH, case studies and results from a cohorted start to treatment Ian Tucker (Bristol, UK)</p> <p>Imaging in metabolic bone disease Alistair Calder (London, UK)</p> <p>From conception to the retailer: how to make your specialised equipment commercially available Jill Massey (London, UK)</p> <p>Surgery and rehabilitation for children with X-linked hypophosphataemia Gabriel Mindler (Vienna, Austria)</p> <p>The patient and parental perspective – XLH Tenna Toft (XLH-Patient Association, Denmark)</p>
12:00-13:00	Sponsored Workshop	
13:30-14:30	<p>Challenge the Expert Organisers: Craig B Langman (Chicago, USA) / Leanne Ward (Ottawa, Canada)</p> <p>Case 1: Fibrous dysplasia Author: Soraya Lopes Sader (Sao Paulo, Brazil) Presenter and discussant: Alison Boyce (Bethesda, USA)</p> <p>Case 2: 4-year old boy with terrible leg pain post bone marrow transplant: Infection? Scurvy? Other? Author: Paivi Miettunen (Calgary, Canada) Presenter and discussant: Nick Shaw (Birmingham, UK)</p>	

	<p>Case 3: Bone fragility, abnormal neurology and bleeding disorder – a challenging case Author: Belinda Crowe (London, UK) Discussant: Craig Munns (Sydney, Australia)</p>
14:30-15:30	<p>Workshop: Osteogenesis Imperfecta</p> <p>Chair: Francis Glorieux (Montreal, Canada)</p> <p>Infant case Nick Bishop (Sheffield UK)</p> <p>Child case Jean-Pierre Salles (Toulouse, France)</p> <p>Adolescent case Craig Munns (Sydney, Australia)</p>
15:30-15:45	<i>Coffee break</i>
15:45-16:45	<p>Symposium: Two years in review</p> <p>Chairs: Nicola Crabtree (Birmingham, UK) / Antonella Forlino (Pavia, Italy)</p> <p>Highlights in basic bone research Clifford Rosen (Maine, USA)</p> <p>Highlights in clinical bone research Nick Shaw (Birmingham, UK)</p>
16:50-17:00	Welcome address
17:15-18:45	Satellite symposium
19:00-19:45	<p><i>Welcome reception</i></p> <p><i>Congress Centre and Gardens</i></p>
	Followed by free time

Sunday 23 June	
08:00-08:45	Meet the expert sessions
	Therapeutic management of hypophosphatemic rickets

	Agnès Linglart (Paris, France)
	Assessment of neuromuscular function and physical activity Alex Ireland (Manchester, UK)
	What you need to know about bone histomorphometry Klaus Klaushofer (Vienna, Austria)
09:00-10:30	Symposium: Bone development
	Chairs: Suzanne Bechtold-Dalla Pozza (Munich, Germany) / Alex Ireland (Manchester, UK)
	Biomechanics of fetal movements Niamh Nowlan (London, UK)
	Mechanical loading and bone development - insights from epidemiological studies Jon Tobias (Bristol, UK)
	Spine development Vicente Gilsanz (Los Angeles, USA)
10:30-11:00	<i>Coffee break and moderated ePoster sessions</i>
	ePoster Screen 1
	Moderator: Munier Nour (Saskatoon, Canada)
P51	Higher dose of burosumab is needed for treatment of children with severe forms of X-linked hypophosphatemia Volha V Zhukouskaya (Le Kremlin Bicetre, France)
P127	Burosumab therapy in pediatric patients with X-linked hypophosphatemia improves body composition Avivit Brener (Tel Aviv, Israel)
P75	Active vitamin D analogues and oral phosphate for the treatment of X-linked hypophosphatemia in paediatric patients: A systematic literature review and survey of expert opinion on current needs Zulf Mughal (Manchester, United Kingdom)
P70	Metabolic bone disease of prematurity – comparing neonatal and endocrine approaches using a nationwide survey Amish Chinoy (Manchester, United Kingdom)
	ePoster Screen 2

	Moderator: Gali Guterman Ram (Bethesda, USA)
P150	Osteogenesis imperfecta: Skeletal outcomes after bisphosphonates discontinuation at final height Marie-Eve Robinson (Montreal, Canada)
P37	Generation of osteogenesis imperfecta type XIV zebrafish models Laura Leoni (Pavia, Italy)
P133	Losartan reduces circulating TGF β and CTX and increases vertebral bone mass in the OIM mouse Nick Bishop (Sheffield, United Kingdom)
P121	An Acvr1[R258G] "conditional on" mouse model of atypical fibrodysplasia ossificans progressiva (FOP) is activin A dependent Sarah Hatsell (Tarrytown, United States)
	ePoster Screen 3
	Moderator: Alessandra Cocca (London, UK)
P99	Pre and post-natal achondroplasia, retrospective series of 64 consecutive cases with analyze of the diagnostic methods and timing issues Genevieve Baujat (Paris, France)
P221	Speech and hearing impairment and respiratory complications in a large cohort of patients with achondroplasia Alessandra Cocca (London, United Kingdom)
P148	Management of foramen magnum stenosis in patients with achondroplasia: relative merit of clinical and radiological indications for foramen magnum decompression William Singleton (Bristol, United Kingdom)
P15	TA-46 prevents premature synchondrosis and restores foramen magnum size in a mouse model of achondroplasia Guylene Rignol (Nice, France)
	ePoster Screen 4
	Moderator: Stephanie Borg (Sheffield, UK)
P110	Cost-effectiveness of a vitamin D supplementation programme in pregnant women and children to prevent rickets in the UK Raja Padidela (Manchester, United Kingdom)
P5	Response of bone to mechanical stimulation in the offspring of MAVIDOS study mothers in a single centre; the effect of antenatal vitamin D supplementation Sujatha Gopal (Sheffield, United Kingdom)

P98	The effect of vitamin D on bone health assessed by radiogrammetry: a double-blind placebo-controlled vitamin D supplementation trial in infants Suma Uday (Birmingham, United Kingdom)
P174	Supplementation of children with type 1 diabetes with milk or pharmacological calcium for improving bone health: A randomized controlled trial Sonal Palande (Pune, India)
11:00-11:30	Charles Slemenda Award Chair: Leanne Ward (Ottawa, Canada)
11:30-12:00	Oral communications
	Chairs: Klaus Klaushofer (Vienna, Austria) / Jon Tobias (Bristol, UK)
OC1	Association between age at puberty and bone accrual up to 25 years-old Ahmed Elhakeem (Bristol, United Kingdom)
OC2	Adolescent pregnancy and bone density in premenopausal women Sonal Palande (Pune, India)
OC3	Osteocyte lacunae characteristics in healthy children Stéphane Blouin (Vienna, Austria)
12:00-13:00	Posters (odd numbers presented)
13:00-14:00	<i>Lunch</i>
14:00-15:30	Symposium: Vitamin D
	Chairs: Jeremy Allgrove (London, UK) (tbc) / Nick Shaw (Birmingham, UK)
	Nutritional rickets – a socioeconomic problem Wolfgang Högl (Linz, Austria)
	Effect of vitamin D on body composition Hope Weiler (Montreal, Canada)
	Vitamin D in pregnancy and offspring immunology Catherine Hawrylowicz (London, UK)

15:30-16:30	Oral communications
	Chairs: Nathalie Alos (Montreal, Canada) / Zulf Mughal (Manchester, UK)
OC4	Early life vitamin D depletion and mechanical loading determine methylation changes in the RXRA, Runx2 and osterix promoters in mice Stephanie Borg (Sheffield, United Kingdom)
OC5	Low birthweight is associated with poorer limb muscle mass and grip strength in middle age: findings from the UK Biobank Imaging Enhancement Elizabeth Curtis (Southampton, United Kingdom)
OC6	Anthropometric characteristics of pediatric patients with hypophosphatasia: data from the Global Hypophosphatasia Patient Registry Wolfgang Högl (Linz, Austria)
OC7	Comparison of zoledronate and pamidronate in children with skeletal disorders: short term safety experience from a single institution Laura Tosi (Washington, United States)
OC8	Bisphosphonate improves hip range of motion and pain but not femoral head sphericity. A multicentre, randomized clinical trial of children with Perthes disease Craig Munns (Westmead, Australia)
OC9	Efficacy and safety of intravenous zoledronic acid for the treatment of pediatric glucocorticoid-induced osteoporosis: An international, randomized placebo-controlled trial Leanne Ward (Ontario, Canada)
16:30-17:00	<i>Coffee break and moderated ePoster sessions</i>
	ePoster Screen 1
	Moderator: Melissa Fiscaletti (Montreal, Canada)
P77	Long-term efficacy profile of asfotase alfa in the treatment of patients with hypophosphatasia: a pooled analysis Michael P Whyte (Saint Louis, United States)
P114	Hypophosphatasia in Japan: ALPL mutation analysis in 98 patients Toshimi Michigami (Izumi, Japan)
P62	Tissue non-specific alkaline phosphatase activity and mineralization capacity of bi-allelic mutations from severe perinatal and asymptomatic hypophosphatasia phenotypes: Results from an in-vitro mutagenesis model Suma Uday (Birmingham, United Kingdom)

P212	Genetic loss of heparanase does not inhibit osteochondromas in Ext1 and Ext2 double heterozygous hereditary multiple osteochondroma mouse model Kalyan Nannuru (Tarrytown, United States)
	ePoster Screen 2
	Moderator: Jill Simmons (Nashville, USA)
P46	Vertebral fractures are more prevalent than long bone fractures in boys with glucocorticoid-treated Duchenne Muscular Dystrophy: Results of a prospective observational study Stefan A Jackowski (Ottawa, Canada)
P156	Patients with nephropatic cystinosis display lower cortical thickness and grip strength Susanne Bechtold-Dalla Pozza (Munich, Germany)
P63	Bone geometry and microarchitecture deficits in children with Alagille Syndrome Joseph Kindler (Philadelphia, United States)
P81	Bone health in adolescent females with anorexia nervosa may be preserved by high lean mass Munier Nour (Saskatoon, Canada)
	ePoster Screen 3
	Moderator: Kristen Pan (Bethesda, USA)
P42	FGF 23 measurements in children with fibrous dysplasia: useful or not? Zilla Huma (London, United Kingdom)
P220	New perspectives in diagnosis and management of optic neuropathy in fibrous dysplasia: utility of optical coherence tomography and computed tomography measurements Kristen Pan (Bethesda, United Kingdom)
P80	Characterization of pain in patients with fibrous dysplasia Tiahna Spencer (Bethesda, United States)
P209	Persistently low trabecular bone mineral density and normal bone strength at the radius over 3 years after simultaneous pancreas kidney transplantation Ondrej Soucek (Prague, Czech Republic)
	ePoster Screen 4
	Moderator: Heike Hoyer-Kuhn (Cologne, Germany)

P141	Hypercalcaemia and osteonecrosis of the jaw in association with denosumab use in the paediatric population Christie-Lee Wall (Westmead, Australia)
P151	The safety and efficacy of denosumab versus zoledronic acid in the treatment of pediatric osteoporosis: A randomized controlled pilot trial Marie-Eve Robinson (Montreal, Canada)
P152	An evaluation of the rebound phenomenon during denosumab therapy in children with low turnover osteoporosis Marie-Eve Robinson (Montreal, Canada)
P129	A smartphone based survey of frequency and severity of adverse effects following bisphosphonate therapy in a tertiary paediatric centre James Blackburn (Liverpool, United Kingdom)
17:00-18:30	Satellite symposium
18:30-19:00	Foramen magnum stenosis in children with achondroplasia working group update
	<i>Free evening</i>

Monday 24 June	
08:00-08:45	Meet the expert sessions
	Ectopic mineralization Frank Rutsch (Münster, Germany)
	Bone in neuromuscular disorders Zulf Mughal (Manchester, UK)
	Skeletal involvement in chronic kidney diseases Craig B Langman (Chicago, USA)
09:00-10:30	Symposium: Bone cells (concurrently with Allied Health Professionals Session)
	Chairs: Meena Balasubramanian (Sheffield, UK / Junya Toguchida (Kyoto, Japan)
	Osteoclast disorders Cristina Sobacchi (Milan, Italy)
	Endoplasmic reticulum stress in osteoblasts Antonella Forlino (Pavia, Italy)
	Clock genes and bone and mineral regulation Masanobu Kawai (Osaka, Japan)
09:00-10:30	Allied Health Professionals Session (concurrently with Bone Cells Symposium)
	Chair: Nicola Crabtree (Birmingham, UK)
P181	Walking quality of children with healed Perthes disease Verity Pacey (Westmead, Australia)
P17	Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults Tandy Aye (California, United States)
P93	Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children David Fennimore (Sheffield, United Kingdom)
P9	Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study Rachel L Duckham (Geelong, Australia)

P177	Feasibility of a 13-week targeted exercise intervention on tibial bone mineral density in adolescents with Developmental Coordination Disorder Jocely Tan (Fremantle, Australia)
P74	Burosumab can improve pain and quality of life for children with X-linked hypophosphataemia and their families: a London centre's experience Robyn Gilbey-Cross (London, United Kingdom)
P185	High impact exercise to improve musculoskeletal outcomes in Crohn's disease: a feasibility questionnaire Lewis Steell (Glasgow, United Kingdom)
P197	A playful type of intervention for infants with osteogenesis imperfecta Rebecca Jones (Sheffield, United Kingdom)
P79	Novel imaging approaches to the quantification of musculoskeletal alterations in X-linked hypophosphatemic rickets (XLH) Adalbert Raimann (Vienna, Austria)
10:30-11:00	<i>Coffee break and moderated ePoster sessions</i>
	ePoster Screen 1
	Moderator: Marie-Eve Robinson (Montreal, Canada)
P27	Response to mechanical stimulation of bone in children with osteogenesis imperfecta and the effect of bisphosphonate therapy Sivagamy Sithambaran (Sheffield, United Kingdom)
P199	Diversity of outcomes in randomised trials of interventions for children with osteogenesis imperfecta Richard McGee (Westmead, Australia)
P137	Reversion to pamidronate after switch to zoledronic acid in children with bone disease Amanda Peacock (Sheffield, United Kingdom)
P143	Intermittent bi-daily sub-cutaneous teriparatide infusion in children with hypoparathyroidism: a single-centre experience Sacha Flammier (Lyon, France)
	ePoster Screen 2
	Moderator: Ahmed Elhakeem (Bristol, UK)
P41	Increased prevalence of fractures in poorly chelated children with beta thalassemia Sonal Palande (Pune, India)

P87	Assessment of bone density by DXA in poorly controlled children with β -Thalassemia: Correction for hepatic iron -overload by manual analysis Sonal Palande (Pune, India)
P89	Use of DXA and pQCT measurements to screen for fracture risk in 3 to 18 year old poorly chelated thalassaemic children Sonal Palande (Pune, India)
P14	Bone health in children with congenital heart disease Marta Erlandson (Saskatoon, Canada)
	ePoster Screen 3
	Moderator: Elizabeth Curtis (Southampton, UK)
P16	Higher neonatal bone mineral content and lower IL-6 levels in offspring of overweight/obese women following antenatal exercise: The IMPROVE randomized controlled trial (RCT) Sumudu Nimali Seneviratne (Colombo, Sri Lanka)
P163	Prenatal oligohydramnios is associated with hip shape in adolescent males Alex Ireland (Manchester, United Kingdom)
P154	Self-reported sedentary time is negatively associated with microarchitecture of the tibia Rebecca Moon (Southampton, United Kingdom)
P9	Do lifestyle factors play a role on bone health in boys diagnosed with Autism Spectrum Disorder? Preliminary data from the Promoting bone and gut health in our children (PROUD) study Rachel L Duckham (Geelong, Australia)
	ePoster Screen 4
	Moderator: Suzanne Bechtold-Dalla Pozza (Munich, Germany)
P17	Sex and maturation effects on trabecular and cortical microarchitecture in children and young adults Tandy Aye (California, United States)
P83	Could digital X-ray radiogrammetry be an alternative for dual energy X-ray absorptiometry Jos Draaisma (Nijmegen, Netherlands)
P11	Reference values of cortical thickness, bone width, and Bone Health Index in metacarpals of children from age 0 y, as determined with an extension of the fully automated BoneXpert bone age method Hans Henrik Thodberg (Hørsholm, Denmark)

P94	Characteristics of ultradistal radius bone density during childhood: Results from the Bone Mineral Density in Childhood Study Joseph Kindler (Philadelphia, United States)
11:00-12:00	Oral communications
	Chairs: Valérie Cormier-Daire (Paris, France) / Agnès Linglart (Paris, France)
OC10	Next-generation antibody-guided enzyme replacement therapy for lysosomal storage diseases Katherine Cygnar (Tarrytown, United States)
OC11	Targeting adeno-associated viral vectors to fractures and the skeleton Lucinda Lee (Westmead, Australia)
OC12	Combination treatment of a novel activin receptor IIB ligand trap and zoledronate improves muscle and bone properties in a mouse model of osteogenesis imperfecta Iris Boraschi-Diaz (Montreal, Canada)
OC13	Analysis of osteogenesis imperfecta in pathology and the effects of 4-phenylbutyric acid using patient-derived fibroblasts and induced pluripotent stem cells Shinji Takeyar (Osaka, Japan)
OC14	Burosumab resulted in greater improvement in clinical outcomes than continuation with conventional therapy in younger (1-4 years-old) and older (5-12 years-old) children with X-linked hypophosphatemia Leanne Ward (Ontario, Canada)
OC15	Sustained efficacy and safety of burosumab, a fully human anti-FGF23 monoclonal antibody, in children and early adolescents with X-linked hypophosphatemia Wolfgang Högler (Linz, Austria)
12:00-13:00	Posters (even numbers presented)
13:00-14:00	<i>Lunch</i>
14:00-15:30	Symposium: Surgical aspects in rare bone disorders
	Chairs: Frank Rauch (Montreal, Canada) / Oliver Semler (Cologne, Germany)
	Orthopedic management of osteogenesis imperfecta in the bisphosphonate era François Fassier (Montreal, Canada)

	Craniosynostoses in rare skeletal disorders Federico Di Rocco (Lyon, France)
	Orthopedic needs in X-linked hypophosphatemic rickets Rudolf Ganger (Vienna, Austria)
15:30-16:00	<i>Coffee break and moderated ePoster sessions</i>
	ePoster Screen 1
	Moderator: Rachel Harrison (Sheffield, UK)
P109	Fracture prevalence in children 0-19 years-old in Mexico: A 10-year cross-sectional analysis Patricia Clark (Mexico City, Mexico)
P22	Tibia microarchitecture in children with recent fractures Rebecca Moon (Southampton, United Kingdom)
P93	Assessing the ability of vibration analysis to differentiate wrist and ankle fractures from sprains in children David Fennimore (Sheffield, United Kingdom)
P25	Short term mechanical stimulation using whole body vibration identifies differences in bone response between prepubertal boys with and without prior fracture Rachel Harrison (Sheffield, United Kingdom)
	ePoster Screen 2
	Moderator: Sonal Palande (Pune, India)
P44	Bone mass and vertebral fractures in South African (SA) children on prolonged oral glucocorticoids (GCs) for chronic non-malignant illnesses Kebashni Thandrayen (Johannesburg, South Africa)
P18	Bone mass and fracture prevalence in Childhood Brain Cancer Survivors (CBCS) 2 or 5 years after off therapy Nataschia di Iorgi (Genova, Italy)
P23	What happens to the skeleton at the time of diagnosis of paediatric cancer? Artemis Doulgeraki (Athens, Greece)
P164	Musculoskeletal deficits persist up to two years despite anti-TNF-alpha antibody therapy in children with Crohn's disease: Results of a prospective, observational inception cohort study Stefan A Jackowski (Ottawa, Canada)

	ePoster Screen 3
	Moderator: Oliver Semler (Cologne, Germany)
P107	Sex differences in the longitudinal associations between body composition and bone stiffness index in European children and adolescents Lan Cheng (Bremen, Germany)
P155	Gender specific paediatric reference data for muscle function parameters assessed using jumping mechanography Sonal Palande (Pune, India)
P159	Determinants of muscle function in 6 to 11 year old rural Indian children Sonal Palande (Pune, India)
P181	Walking quality of children with healed Perthes disease Verity Pacey (Westmead, Australia)
	ePoster Screen 4
	Moderator: Carla Caffarelli (Siena, Italy)
P120	Mutational and phenotypic spectra in 137 Russian patients with inherited forms of rickets Kristina Kulikova (Moscow, Russian Federation)
P125	SCN8a mutations and osteoporosis. Is osteocyte dysfunction the cause or the consequence? Gillian O'Donnell (Dublin, Ireland)
P113	Next-generation sequence and biomarker levels in the patients with early-onset chronic non-bacterial osteomyelitis from North Caucasian region of Russia Mikhail Kostik (St Petersburg, Russian Federation)
P13	Clinical implications of modeling the maturational spurt Melanie Boeyer (Missouri, United States)
16:00-17:15	Oral Communications
	Chairs: Alison Boyce (Bethesda, USA) / Craig B Langman (Chicago, USA)
OC16	A natural history study of generalized arterial calcification of infancy (GACI) and autosomal recessive hypophosphatemic rickets (ARHR2) due to ENPP1 or ABCC6 deficiency: Interim analysis Yvonne Nitschke (Münster, Germany)
OC17	Growth curves for children with X-linked hypophosphatemia

	Meng Mao (Novato, United States)
OC18	Developing a human-mouse hybrid model of osteogenesis imperfecta for investigating new therapies for children Fawaz Arshad (Sheffield, United Kingdom)
OC19	Altered α hydroxylation complex in bone homeostasis Francesca Tonelli (Pavia, Italy)
OC20	Identifying the role of NBAS in bone fragility using zebrafish and exploring therapeutic targets to reverse NBAS activity Meena Balasubramanian (Sheffield, United Kingdom)
OC21	New mouse model with IFITM5 S42L for atypical type VI osteogenesis imperfecta Gali Guterman Ram (Bethesda, United States)
OC22	Bone tissue phenotyping reveals increased matrix mineralization, elevated osteocyte lacunar density and altered vascularity in a new OI mouse model carrying a leucine substitution for the BRIL p.Serine42 residue Ghazal Hedjazi (Vienna, Austria)
17:30-19:00	Satellite Symposium
20:00-23:00	<i>Conference Dinner</i> <i>Stieglkeller</i>

Tuesday 25 June	
08:00-08:45	Meet the expert sessions
	Genetic testing for recurrent fractures – when and what? Outi Mäkitie (Helsinki, Finland)
	Management of fibrous dysplasia Alison Boyce (Bethesda, USA)
	Vibration treatment Oliver Semler (Cologne, Germany)
09:00-10:00	Symposium: New medical therapies of bone dysplasias
	Chairs: Laurence Legeai-Mallet (Paris, France) / Coen Netelenbos (Amsterdam, Netherlands)
	Diagnosis of bone dysplasia Valérie Cormier-Daire (Paris, France)
	Achondroplasia Noriyuki Namba (Osaka, Japan)
10:00-11:00	Oral communications
	Chairs: Moira Cheung (London, UK) / Noriyuki Namba (Osaka, Japan)
OC23	Effects of the FGF2 aptamer on growth plate cartilage development of achondroplasia patient-specific iPS cells in a xenograft model Takeshi Kimura (Osaka, Japan)
OC24	TA-46, a recombinant soluble FGFR ₃ receptor for the treatment of achondroplasia, is safe and well-tolerated in healthy volunteers Samuel Collins (Basel, Switzerland)
OC25	TransCon CNP: Potential for a once weekly novel therapy in children with achondroplasia Kamal Bharucha (Palo Alto, United States)
OC26	[¹⁸ F] NaF PET/CT the first tool to diagnose chronic activity in FOP at all ages? Coen Netelenbos (Amsterdam, Netherlands)
OC27	Palovarotene inhibits the development of new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP) Richard Keen (Stanmore, United Kingdom)
LB	Late breaker

11:00- 11:15	<i>Coffee break</i>
11:15- 11:30	Presentation of Awards
	Gabriele Häusler (Vienna, Austria) / Frank Rauch (Montreal, Canada) / Leanne Ward (Ottawa, Canada)
11:30- 12:30	Symposium: Approaches to treating low bone mass disorders
	Chairs: Outi Mäkitie (Helsinki, Finland) / Peter Simm (Sydney, Australia)
	TGFbeta inhibition in osteogenesis imperfecta Ingo Grafe (Houston, USA)
	Antiresorptive treatment Leanne Ward (Ottawa, Canada)
12:30	Close and final remarks Nick Bishop (Sheffield, UK)
12:35	<i>Buses to airport</i>